| | | | | | | | |
| Zar-Kessler C, | et al. | Understanding the gastrointestinal manifestations of Fabry disease: promoting prompt diagnosis | Therap Adv Gastroenterol | | 9 | 4 | 626-634 | 2016 |
| Tadevosyan A | | Fabry disease: A fundamental genetic modifier of cardiac function | Curr Res Transl Med | | 65 | 1 | 10-14 | 2017 |
| Schiffmann R, | et al. | Is it Fabry disease? | Genet Med | | 18 | 12 | 1181-1185 | 2016 |
| Cardoso GMF, | et al. | Bioenergetics dysfunction, mitochondrial permeability transition pore opening and lipid peroxidation induced by hydrogen sulfide as relevant pathomechanisms underlying the neurological dysfunction characteristic of ethylmalonic encephalopathy | Biochim Biophys Acta | | 1863 | 9 | 2192-2201 | 2017 |
| Burnett JR, | Hooper AJ, Hegele RA | Familial Lipoprotein Lipase Deficiency | GeneReviews-« Internet | GeneReviews-« Internet | 0 | 0 | | 2017 |
| Dionisi-Vici C, | et al. | Liver transplant in ethylmalonic encephalopathy: a new treatment for an otherwise fatal disease | Brain | | 139 | 4 | 1045-1051 | 2016 |
| Citro V, | et al. | The Large Phenotypic Spectrum of Fabry Disease Requires Graduated Diagnosis and Personalized Therapy: A Meta-Analysis Can Help to Differentiate Missense Mutations | Int J Mol Sci | | 17 | 0 | 12 | 2016 |
| El Dib R, | et al. | Enzyme replacement therapy for Anderson-Fabry disease | Cochrane Database Syst Rev | | 70 | 0 | | 2016 |
| K-¦l-¦c M, | et al. | Successful treatment of a patient with ethylmalonic encephalopathy by intravenous N-acetylcysteine | Metab Brain Dis | | 32 | 3 | 293-296 | 2017 |
| Schiffmann R, | Ries M | Fabry Disease: A Disorder of Childhood Onset | Pediatr Neurol | | 64 | 0 | 10-20 | 2016 |
| Bokhari SR, | Al Aboud A | Fabry Disease | StatPearls Internet | | 0 | 0 | | 2017 |
| Ranieri M, | et al. | Fabry Disease: Recognition, Diagnosis, and Treatment of Neurological Features | Curr Treat Options Neurol | | 18 | 7 | 33 | 2016 |
